Mumbai, January 27, 2025 – Supriya Lifescience Limited (NSE: SUPRIYA, BSE: 543434) has reported a strong financial performance for Q3 FY25, with Profit after tax (PAT) rising 57% year-over-year (YoY) to ₹46.78 crore. The company's revenue grew 33% YoY to ₹185.65 crore, driven by robust demand across its API (active pharmaceutical ingredient) portfolio.
Key Financial Highlights (Q3 FY25 vs. Q3 FY24)
- Revenue: ₹185.65 crore (+33% YoY)
- Gross Profit: ₹123.87 crore (+45% YoY)
- EBITDA: ₹65.95 crore (+59% YoY)
- EBITDA Margin: 35.50%, up from 29.60%
- PAT: ₹46.78 crore (+57% YoY)
- PAT Margin: 25.2%, up from 21.30%
- EPS: ₹5.82, up from ₹3.70 in Q3 FY24
Management Commentary
Dr. Satish Wagh, Chairman & Whole-Time Director, Supriya Lifescience, stated:"Our Q3 FY25 results underscore Supriya Lifescience's commitment to delivering value through operational excellence and strategic growth. The 33% YoY revenue growth and a 45% surge in gross Profit reflect our strong market presence and execution across therapeutic segments. With EBITDA and PAT margins improving to 35% and 25%, respectively, we continue to invest in sustainable growth while maintaining profitability."